JP2017515815A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515815A5
JP2017515815A5 JP2016565473A JP2016565473A JP2017515815A5 JP 2017515815 A5 JP2017515815 A5 JP 2017515815A5 JP 2016565473 A JP2016565473 A JP 2016565473A JP 2016565473 A JP2016565473 A JP 2016565473A JP 2017515815 A5 JP2017515815 A5 JP 2017515815A5
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
acid sequence
interferon alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016565473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515815A (ja
JP6550400B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/001600 external-priority patent/WO2015181641A2/en
Publication of JP2017515815A publication Critical patent/JP2017515815A/ja
Publication of JP2017515815A5 publication Critical patent/JP2017515815A5/ja
Application granted granted Critical
Publication of JP6550400B2 publication Critical patent/JP6550400B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016565473A 2014-05-01 2015-05-01 レナリドミド及びポリペプチド構築物の組合せ、及びその使用 Active JP6550400B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461986913P 2014-05-01 2014-05-01
US61/986,913 2014-05-01
PCT/IB2015/001600 WO2015181641A2 (en) 2014-05-01 2015-05-01 Combination of lenalidomide and polypeptide construct, and uses thereof

Publications (3)

Publication Number Publication Date
JP2017515815A JP2017515815A (ja) 2017-06-15
JP2017515815A5 true JP2017515815A5 (enExample) 2018-06-14
JP6550400B2 JP6550400B2 (ja) 2019-07-24

Family

ID=54354398

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016565473A Active JP6550400B2 (ja) 2014-05-01 2015-05-01 レナリドミド及びポリペプチド構築物の組合せ、及びその使用

Country Status (19)

Country Link
US (3) US9636334B2 (enExample)
EP (1) EP3137505B1 (enExample)
JP (1) JP6550400B2 (enExample)
KR (1) KR102412023B1 (enExample)
CN (1) CN106536562B (enExample)
AU (1) AU2015265624B2 (enExample)
BR (1) BR112016025437A2 (enExample)
CA (1) CA2945902C (enExample)
CL (1) CL2016002733A1 (enExample)
EA (1) EA033359B1 (enExample)
ES (1) ES2736121T3 (enExample)
IL (1) IL248394B (enExample)
MA (1) MA39836A (enExample)
MX (1) MX375746B (enExample)
NZ (1) NZ725487A (enExample)
PE (1) PE20161392A1 (enExample)
PT (1) PT3137505T (enExample)
UA (1) UA119352C2 (enExample)
WO (1) WO2015181641A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP3559049B1 (en) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
NZ713641A (en) 2013-04-29 2019-08-30 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
IL251822B2 (en) * 2014-10-29 2023-03-01 Teva Pharmaceuticals Australia Pty Ltd Variants of interferon alpha-2-b
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CN108883180B (zh) 2016-02-05 2023-07-07 奥里尼斯生物科学私人有限公司 Clec9a结合剂及其用途
BR112019000544A2 (pt) 2016-07-15 2019-04-24 Takeda Pharmaceutical Company Limited métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática
EP3544612A4 (en) 2016-11-23 2020-05-13 Acetylon Pharmaceuticals, Inc. PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
WO2018237159A1 (en) 2017-06-21 2018-12-27 Cephalon, Inc. Cation exchange chromatography wash buffer
CN111278858B (zh) 2017-07-11 2024-07-23 指南针制药有限责任公司 结合人cd137的激动剂抗体及其用途
CN111328286B (zh) 2017-08-09 2024-08-23 奥里尼斯生物科学有限公司 Pd-1和pd-l1结合剂
KR102659140B1 (ko) 2017-08-09 2024-04-19 오리오니스 바이오사이언시스 인코포레이티드 Clec9a 결합제 및 그의 용도
CA3069930A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. Cd8 binding agents
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
EP3737702A1 (en) 2018-01-12 2020-11-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
KR102286497B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 다양한 용량의 레날리도마이드의 경구용 정제 조성물
WO2019199134A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 약제학적 조성물
WO2019199135A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
JP7581052B2 (ja) * 2018-04-13 2024-11-12 サムヤン ホールディングス コーポレイション レナリドミドの経口用コーティング錠剤組成物
KR102286500B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
RU2694672C1 (ru) * 2018-04-27 2019-07-16 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Вариабельные домены лёгкой и тяжёлой цепи мышиного моноклонального антитела против интерферона альфа (IFN-α) человека, антигенсвязывающий фрагмент (Fab) против IFN-α человека, содержащий указанные домены
CA3108795A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. Sirp1a targeted chimeric proteins and uses thereof
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
EP3947429A4 (en) 2019-03-28 2023-05-17 Orionis Biosciences, Inc. CLEC9A-BASED CHIMERA PROTEIN COMPLEXES
CN113993543B (zh) 2019-06-10 2024-07-12 武田药品工业株式会社 使用抗cd38抗体的组合疗法
JP2023505168A (ja) 2019-12-03 2023-02-08 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インターフェロン会合抗原結合タンパク質及びこれらの使用
EP4525911A1 (en) 2022-05-18 2025-03-26 Takeda Pharmaceutical Company Limited Anti-cd38 fusion protein formulation
WO2023227949A1 (en) * 2022-05-27 2023-11-30 Takeda Pharmaceutical Company Limited Dosing of cd38-binding fusion protein
TW202430548A (zh) * 2022-09-29 2024-08-01 日商武田藥品工業股份有限公司 Ｃｄ３８結合融合蛋白組合療法

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5976531A (en) 1990-04-19 1999-11-02 The Dow Chemical Company Composite antibodies of human subgroup IV light chain capable of binding to tag-72
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
JP3854306B2 (ja) 1991-03-06 2006-12-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ヒト化及びキメラモノクローナル抗体
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
ES2191702T3 (es) 1994-03-17 2003-09-16 Merck Patent Gmbh Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
DK0706799T3 (da) 1994-09-16 2002-02-25 Merck Patent Gmbh Immunkonjugater II
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
DE69638269D1 (de) 1995-06-14 2010-11-18 Univ California Hochaffine humane antikörper gegen tumorantigene
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
CN1217750A (zh) 1996-05-04 1999-05-26 曾尼卡有限公司 抗cea的单克隆抗体,包括所述抗体的偶联物及其在adept系统中的治疗应用
US6417337B1 (en) 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
MXPA01003790A (es) 1998-10-16 2002-09-18 Biogen Inc Proteinas de fusion beta - interferon y sus usos.
DK1137789T3 (da) 1998-12-09 2010-11-08 Phyton Holdings Llc Fremgangsmåde til fremstilling af et glycoprotein med glycosylering af human type
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
CN1763097B (zh) 1999-01-15 2011-04-13 杰南技术公司 具有改变的效应功能的多肽变体
JP4778617B2 (ja) 1999-03-12 2011-09-21 ジョージタウン ユニバーシティ マトリプターゼ、セリンプロテアーゼおよびその応用
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
ES2269366T3 (es) 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
WO2001097844A1 (en) 2000-06-22 2001-12-27 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
ES2330330T3 (es) 2000-06-28 2009-12-09 Glycofi, Inc. Procedimiento de produccion de glucoproteinas modificadas.
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
ES2344592T3 (es) 2001-01-05 2010-09-01 Pfizer Inc. Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
FR2823764B1 (fr) 2001-04-24 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
DK1409544T3 (da) 2001-07-03 2009-10-26 Genentech Inc Humane DR4-antistoffer og anvendelser deraf
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
KR100668538B1 (ko) 2002-01-09 2007-01-16 메다렉스, 인코포레이티드 Ｃｄ３０에 대한 인간 모노클로날 항체
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
ES2350477T5 (es) 2002-03-01 2020-05-06 Immunomedics Inc Internalización de anticuerpos anti-CD74 y métodos de uso
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
JP2006502110A (ja) 2002-07-03 2006-01-19 イミュノジェン・インコーポレーテッド 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用
ES2343518T3 (es) 2002-09-09 2010-08-03 Hanall Biopharma Co., Ltd. Polipeptidos interferon alfa modificados resistentes a proteasas.
CA2498284A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2516293A1 (en) 2003-02-18 2004-09-02 Tim Jones Fusion proteins of interferon alpha muteins with improved properties
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
JP4810431B2 (ja) 2003-11-04 2011-11-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｂ細胞に関連する癌に対する治療方法
SI2511297T1 (sl) 2004-02-06 2015-07-31 Morphosys Ag Proti -CD38 humana protitelesa in njihova uporaba
KR20140066259A (ko) 2004-02-06 2014-05-30 모르포시스 아게 항-ｃｄ３８ 인간 항체 및 그의 용도
US8034352B2 (en) 2005-04-06 2011-10-11 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US7273608B2 (en) 2004-03-11 2007-09-25 City Of Hope Humanized anti-CEA T84.66 antibody and uses thereof
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CA2601417C (en) 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
JP5222559B2 (ja) 2004-10-15 2013-06-26 シアトル ジェネティックス， インコーポレイテッド 癌および免疫障害の処置および予防のための抗ｃｄ７０抗体ならびにその使用
MX2007011064A (es) 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
EP2799451A1 (en) * 2005-05-24 2014-11-05 MorphoSys AG Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38
CN101184771A (zh) 2005-05-26 2008-05-21 先灵公司 干扰素－IgG融合体
AU2006263331B2 (en) 2005-06-29 2012-02-16 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Recombinant interferon alpha2 (IFNalpha2) mutants
EA021669B1 (ru) 2005-07-18 2015-08-31 Амджен Инк. Нейтрализующие антитела человека против b7rp1
EP1934261B1 (en) 2005-09-26 2014-10-29 Medarex, L.L.C. Human monoclonal antibodies to cd70
US20070190068A1 (en) 2005-10-10 2007-08-16 Richard Hart uPAR-binding molecule-drug conjugates and uses thereof
RU2425841C2 (ru) 2005-10-12 2011-08-10 МорфоСис АГ Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38
JP2009513147A (ja) 2005-10-31 2009-04-02 アメリカ合衆国 ヒト糖タンパクｎｍｂをターゲットにする抗体および免疫毒素
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
CN101045156B (zh) 2006-03-29 2012-05-02 刘宏利 特异靶向性药物及其用途
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
FR2905375A1 (fr) 2006-08-29 2008-03-07 Biomethodes Sa Variants ameliores de l'interferon alpha humain
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
HRP20191115T1 (hr) * 2006-09-26 2019-09-20 Genmab A/S Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US7723485B2 (en) 2007-05-08 2010-05-25 Genentech, Inc. Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
US20110045007A1 (en) 2007-05-31 2011-02-24 Genmab A/S Fusion or linked proteins with extended half life
CA2695382A1 (en) 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health Of Human Services, National Institutes Of A fold-back diabody diphtheria toxin immunotoxin and methods of use
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
EP3150218B1 (en) 2007-09-21 2021-09-08 The Regents Of The University Of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
US20100261275A1 (en) 2007-12-10 2010-10-14 Yves Durocher Production of Recombinant Interferon Proteins
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
HRP20140604T1 (hr) 2007-12-26 2014-09-12 Biotest Ag Sredstva koja djeluju na cd138 i njihova upotreba
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
MA33194B1 (fr) 2009-03-16 2012-04-02 Cephalon Australia Pty Ltd Anticorps humanisés ayant une activité antitumorale
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
US8909257B2 (en) 2010-06-19 2014-12-09 Qualcomm Incorporated Positioning protocol conveyance
WO2012041800A1 (en) * 2010-09-27 2012-04-05 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
US9505826B2 (en) 2010-12-22 2016-11-29 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP3559049B1 (en) * 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
US9492562B2 (en) 2012-01-20 2016-11-15 Vib Vzw Targeted human-interferon fusion proteins
PL2822575T3 (pl) 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
WO2014028502A1 (en) 2012-08-13 2014-02-20 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
US20150353485A1 (en) 2013-01-25 2015-12-10 Bayer Materialscience Ag Security element having volume hologram and printed feature
NZ713641A (en) 2013-04-29 2019-08-30 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
IL251822B2 (en) * 2014-10-29 2023-03-01 Teva Pharmaceuticals Australia Pty Ltd Variants of interferon alpha-2-b

Similar Documents

Publication Publication Date Title
JP2017515815A5 (enExample)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2015520758A5 (enExample)
JP2011046732A5 (enExample)
MX2018015584A (es) Anticuerpos anti-pd-l1 y usos de los mismos.
HRP20201656T1 (hr) Neutralizacija inhibitornih putova u limfocitima
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
CL2013003373A1 (es) Proteina de union al antigeno de maduración de linfocitos b (bcma); composicion farmacéutica que comprende la proteína; uso para preparar un medicamento util para tratar mieloma multiple o (mm) leucemia linfocitica cronica (cll).
JP2016512551A5 (enExample)
JP2017528462A5 (enExample)
JP2020500538A5 (enExample)
JP2018534933A5 (enExample)
CN109843927A (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
JP2017507954A5 (enExample)
JP2011514150A5 (enExample)
RU2019119862A (ru) Антитела к компоненту комплемента c5
JP2018500014A5 (enExample)
JP2016536361A5 (enExample)
JP2017529838A5 (enExample)
NZ631007A (en) Anti-c5 antibodies having improved pharmacokinetics
JP2018513149A5 (enExample)
FI3699198T3 (fi) Menetelmiä kasvaimen hoitoon bispesifistä CD3XCD20-vasta-ainetta käyttämällä
RU2016100892A (ru) Антитела против tweakr и их применение
RU2020124153A (ru) Гуманизированные антитела к cd19 человека и способы их применения
EP4435009A3 (en) Claudin6 antibodies and methods of treating cancer